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Timely molecular diagnosis of RB1 mutations enables earlier treatment, lower risk, and better health outcomes for
patients with retinoblastoma; empowers families to make informed family-planning decisions; and costs less than
conventional surveillance. However, complexity has hindered clinical implementation of molecular diagnosis. The
majority of RB1 mutations are unique and distributed throughout the RB1 gene, with no real hot spots. We devised
a sensitive and efficient strategy to identify RB1 mutations that combines quantitative multiplex polymerase chain
reaction (QM-PCR), double-exon sequencing, and promoter-targeted methylation-sensitive PCR. Optimization of
test order by stochastic dynamic programming and the development of allele-specific PCR for four recurrent point
mutations decreased the estimated turnaround time to !3 wk and decreased direct costs by one-third. The multistep
method reported here detected 89% (199/224) of mutations in bilaterally affected probands and both mutant
alleles in 84% (112/134) of tumors from unilaterally affected probands. For 23 of 27 exons and the promoter
region, QM-PCR was a highly accurate measure of deletions and insertions (accuracy 95%). By revealing those
family members who did not carry the mutation found in the related proband, molecular analysis enabled 97 at-
risk children from 20 representative families to avoid 313 surveillance examinations under anesthetic and 852 clinic
visits. The average savings in direct costs from clinical examinations avoided by children in these families sub-
stantially exceeded the cost of molecular testing. Moreover, health care savings continue to accrue, as children in
succeeding generations avoid unnecessary repeated anaesthetics and examinations.
Introduction
Mutation and subsequent biallelic inactivation of the hu-
man retinoblastoma susceptibility gene, RB1 (GenBank
accession number L11910), on chromosome 13q14
(Friend et al. 1986), initiates retinoblastoma (MIM
180200), a tumor of the eye in children. Bilateral reti-
noblastoma arises from predisposition imposed by a de
novo or inherited germline RB1 mutation, whereas in
85% of children with unilateral retinoblastoma and no
known family history, both RB1 alleles are mutated in a
developing somatic retinal cell that becomes malignant.
Precise identification of the RB1 mutations that ac-
count for retinoblastoma in each family has been pre-
dicted to enhance the quality of clinical management of
the affected patient and relatives at risk (Gallie et al.
1995). Children at risk to develop retinoblastoma un-
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dergo a series of clinical examinations, including exam-
ination under anesthetic (EUA), to diagnose and treat
tumors as early as possible. If the proband’s RB1 gene
status is determined by molecular testing, only those rel-
atives with the mutation require clinical surveillance,
whereas those proven to be noncarriers require no further
examinations. The direct costs of molecular testing are
predicted to be significantly less than conventional clin-
ical examinations for each family (Noorani et al. 1996).
If a family’s mutation is known, prenatal molecular test-
ing allows careful planning of perinatal management for
infants with RB1 mutations, including premature deliv-
ery to facilitate early treatment and optimize visual out-
come (Gallie et al. 1999).
Despite clear clinical benefits of molecular testing for
retinoblastoma, RB1 mutation detection has not been
widely implemented. Highly heterogeneous inactivating
mutations are distributed along the entire length of the
gene, which suggests that no single technology will be
fully sensitive and efficient and that testing for RB1
mutations may be costly. Cost-effective health care
would logically require that a molecular test method-
ology be shown to be ethically justified, sensitive, ac-
curate, and economically feasible (Ganguly and Wil-
liams 1997; Rebbeck et al. 1997) before it becomes
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routine clinical care. Although there are many articles
on ethical standards and the clinical relevance of genetic
testing in general, there is little published analysis of the
impact of molecular test sensitivity and efficiency on
health care.
Here we present a sensitive and efficient strategy to
screen probands with retinoblastoma forRB1mutations.
The method combines quantitative multiplex PCR (QM-
PCR), two-dye double-exon sequencing, and, for unilat-
eral tumors, methylation-sensitive PCR (MS-PCR). The
potential of allele-specific PCR (AS4-PCR) to increase
efficiencywas also evaluated.We used stochastic dynamic
programming to model the search problem and to derive
optimal orderings of 19 different tests for two proband
groups: (1) probandswith bilateral and familial unilateral
retinoblastoma and (2) probandswith sporadic unilateral
retinoblastoma. Efficient use of molecular testing reduced
the estimated surveillance cost for 20 randomly selected
families with retinoblastoma.
Material and Methods
Patient Samples
We examined 134 probands with unilateral, nonfam-
ilial retinoblastoma and 224 probands with bilateral or
familial unilateral retinoblastoma, referred from Canada,
the United States, and several other countries. All partic-
ipating families provided informed consent for the re-
search team to perform clinical tests and to use the
samples for retinoblastoma research in an anonymous
manner. No person selected the option to exclude their
sample or information from research, in which case their
information would have been excluded from this analysis.
Peripheral blood lymphocytes (PBL) of patients with
bilateral and familial unilateral retinoblastoma were
studied for RB1 mutations. Since few (15%) of the per-
sons with sporadic unilateral retinoblastoma are pre-
dicted to have a germline RB1 mutation, failure to find
a mutation in PBL is of marginal predictive value. There-
fore, we searched unilateral tumor DNA for biallelic
inactivating mutations and then examined PBL for those
specific mutant alleles, to rule a germline mutation in or
out.
Total genomic DNA from PBL and tumor samples was
extracted using the Puregene kit, according to the man-
ufacturer’s directions (Gentra).
QM-PCR
We used QM-PCR to screen for changes in exon size
and copy number. All 27 exons of the gene were am-
plified using intronic primers designed to include splice
sites. The 3′ end of the promoter, containing binding sites
for ATF, E2F, SP1, AP1, and HRE elements (T’Ang et
al. 1989; Gill et al. 1994), was amplified as a single
fragment. Amplification was performed in six multiplex
sets containing 1–8 fluorescent-labeled primer pairs (Cy
5.5) that yielded products of different sizes to allow si-
multaneous visualization of fragments. Reactions were
performed with the AmpliTaqDNA polymerase kit (Ap-
plied Biosystems). PCR conditions were optimized so
that each exon was amplified quantitatively. Either a
282-bp or a 329-bp product from exon 4 of the human
retinaldehyde-binding protein gene (chromosome 15)
was used as an internal control for quantitation against
external controls known to have the following RB1 stat-
uses: nullisomic (WERI-RB1 retinoblastoma cell line)
(McFall et al. 1977), monosomic (EL cell line) (Benedict
et al. 1983), and diploid (normal). Amplified products
were heat denatured, separated on a 6% polyacrylamide
gel, and analyzed using the OpenGene Automated DNA
System (Visible Genetics). Fragment detection and sub-
sequent calculations were performed by Gene Objects
3.1 software (Visible Genetics). Ratios of RB1-derived
peaks to internal control peaks were used to calculate
gene copy number. Size standards labeled with Cy5.5
were used to identify aberrantly migrating bands indi-
cating suspect intraexonic insertion or deletion, which
were verified and further characterized by bidirectional
sequencing.
When QM-PCR indicated suspect insertion or dele-
tion involving one or more exons, long PCR was used
to distinguish between true genetic alteration and arti-
facts generated by inefficient amplification due to in-
tronic primer site polymorphisms. Amplimers were gen-
erated from genomic DNA through use of primers
flanking the span of exons suspected to be deleted, using
the XL PCR kit according to the manufacturer’s instruc-
tions (Perkin-Elmer). PCR products were analyzed by
conventional agarose gel electrophoresis.
We collected 3,223 QM-PCR readings from samples
known to have either two copies or only one copy of a
particular exon. Then we estimated the statistical power
of QM-PCR to distinguish between one-copy and two-
copy genotypes. The number of data points for two-
copy QM-PCR readings was 48–80 per exon, and, for
one-copy readings, 4–17 data points. For each exon and
the promoter region, statistical power was estimated by
computing the two-copy confidence level associatedwith
the lowest critical value that exceeds all observed one-
copy QM-PCR readings for the exon in question.
Sequencing
Duplex PCRs that amplify pairs of exons were per-
formed with the AmpliTaq DNA polymerase kit (Ap-
plied Biosystems). Each pair of exons was sequenced
simultaneously through use of the Cy5/Cy5.5 Dye
Primer Cycle Sequencing Kit (Amersham, Quebec/Visi-
ble Genetics). Each primer mixture contained two prim-
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ers, labeled with either Cy5 or Cy5.5, that target the
amplified exons. Primers were designed to include an
average of 50 bp of intronic sequence to encompass rec-
ognized splice sites. Exons were duplexed on the basis
of similar mutation yields (to load early tests with pos-
itive results) or compatible reaction conditions. To se-
quence all 27 exons and the promoter region of RB1
required 14 duplex sequencing reactions. The sequences
generated were compared with wild-typeRB1 (GenBank
accession number L11910) for sequence alterations, us-
ing the OpenGene Automated DNA System and Gene
Librarian software, version 3.1 (Visible Genetics).
Conventional nomenclature was used to name mu-
tations in a way meant to clearly identify the predicted
result on the expected protein product. Nucleotide po-
sition was numbered on the basis of the cDNA sequence,
using the first base of the initiator codon as cDNA po-
sition number 1. RB1 mutations are also commonly re-
ported with reference to the genomic sequence (GenBank
accession number L11910) (Antonarakis 1998; Loh-
mann et al. 2002). Splice mutations were named ac-
cording to their position relative to the closest exonic
base where the first base 5′ of the intronic-exonic bound-
ary was denoted as 1 (and, similarly, the first base 3′
of the intronic-exonic boundary was denoted as 1).
When relevant, mutations were also named by their ef-
fect on the amino acid at specific codons.
AS4-PCR
PCR primers were designed for specific multiplex am-
plification of mutant sequences of four recurrent mu-
tations: R358X, R251X, R579X, and R455X, in frag-
ments of 202, 253, 287, and 730 bp, respectively. The
sense primers were specific for either the wild-type or
mutant genomic DNA templates at the ultimate 3′ base
position. Reactions were performed with the AmpliTaq
DNA polymerase kit (Applied Biosystems). PCR con-
ditions were optimized so that samples with these mu-
tations would amplify strongly and only faint amplifi-
cation would occur in the absence of the mutant alleles
(for primer and template mismatches). Products were
resolved by 2% agarose gel electrophoresis, and the in-
tensity of the amplified band indicated a mutant allele.
Promoter Methylation Assay
For patients with unilateral retinoblastoma, no family
history, and no more than one somatic mutation in tu-
mor revealed by QM-PCR and sequence analysis, we
tested for methylation of the RB1 promoter. The sodium
bisulfite conversion and methylation-specific PCR (MS-
PCR) was performed as described by Zeschnigk et al.
(1999). PCR products from hypermethylated (201 bp)
and normal (154 bp) RB1 promoter were separated on
a 2% agarose gel.
Performance Measures
Sensitivity was calculated from the clinical samples by
the mutation-detection strategy that combines QM-
PCR, double-exon sequencing, and MS-PCR. The sen-
sitivity of allele-specific PCR was estimated as the ability
to correctly identify four different mutations in samples
that were discovered, by sequencing, to contain those
mutations. For each assay, the cost (supplies and labor)
and time to perform the assay was measured. The op-
timal rank order for assays was determined by using
stochastic dynamic programming to minimize forecast
average cost (or turnaround time, if desired), under the
assumption that the mutation frequency spectrum ob-
served for our sample is representative of the population.
Optimal Test Orders
We used the following strategy to approximate the
optimal sequence of 19 different molecular assays to
discover unknown retinoblastoma mutations. Working
backwards from diagnosed mutations, we listed themin-
imal set of assays required to completely diagnose each
family’s mutation(s). For each of 24 permutations of
QM-PCR multiplexes, we counted the number of mu-
tations first detected by each QM-PCR multiplex when
performed in the permuted sequence, to identify the per-
mutation(s) with the fastest discovery rate.
For each order of the 19 assays with QM-PCR assays
in the optimal sequence, we calculated the total direct
cost of performing assays in the chosen order until the
first sign of a mutation was discovered, as well as the
cost of confirming the diagnosis by certain other assays
in the minimal set, family by family. The average cost
per proband to diagnose unknown mutations, for fam-
ilies with germline and sporadic mutations, is the per-
formance measure used to rank candidate assay per-
mutations. The direct cost calculation for unilaterally
affected probands included every test until the first mu-
tation (M1) was discovered, the test required to deter-
mine whether M1 is a germline mutation, subsequent
tests performed until the second mutation (M2) was dis-
covered if the first mutation was not in the germline,
and the test required to determine whether M2 was a
germline mutation.
Clinical Impact of RB1 Mutation Identification
For each relative found to have the RB1 mutation of
the proband, we noted the ocular outcome. The impact
of molecular analysis was compared with conventional
clinical screening of 20 families with retinoblastoma
whose complete pedigree information was available, in-
cluding for second-degree child relatives. The number of
clinical examinations counted for each person at risk
followed standard surveillance protocols for relatives at
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different ages and with differing levels of risk. Each child
at high risk to have retinoblastoma would convention-
ally receive eight EUAs and five clinic examinations, de-
pending on risk group, until age 4 years, and approxi-
mately eight clinic visits until age 10 years. Relatives
who are older than 10 years are exempt from surveil-
lance examinations, because the risk of developing ret-
inoblastoma tumors becomes very small. Relatives at
medium risk, such as first cousins of bilateral probands,
would conventionally receive five EUAs and 14 clinic
visits, and those at low risk (first cousins of unilateral,
nonfamilial probands) would conventionally receive no
EUAs and 17 clinic visits.
The direct costs of surveillance for retinoblastoma
were estimated, for each family, with and without mo-
lecular testing. To estimate clinical surveillance costs, we
adjusted the 1994 cost of EUA and clinic examination
at the Hospital for Sick Children (Noorani et al. 1996)
for 3% inflation (the average change in the TorontoCon-
sumer Price Index). Costs for EUA and for clinical ex-
amination were estimated at Can$740 (US$468) and
Can$108 (US$68), respectively. Cost of molecular anal-
ysis was estimated at Can$5,000 (US$3,200) to search
for an unknown mutation, and Can$500 (US$320) to
test a relative at risk for a known mutation. Under the
molecular testing strategy, the carrier statuses of the pro-
bands and their first-degree relatives determined which,
if any, additional relatives needed molecular testing.Mo-
lecular test results were assumed to be available 60 d
after each proband’s clinical diagnosis, except for those
families in which the causal mutation could not be
identified.
Results
Mutation Types and Recurrent Mutations
All functional classes of mutations were identified (ta-
ble 1). The germline mutations in 199 probands with
bilateral retinoblastoma were 93% null, 6% in-frame,
and 1% in the promoter region. The germline mutations
identified in 30 probands with unilateral retinoblastoma
(both familial and nonfamilial) were 57% null, 40% in-
frame, and 3% promoter, consistent with these muta-
tions being associated with reduced penetrance. Themu-
tant alleles that were identified in retinoblastoma tumors
from 112 unilaterally affected probands but were not
detectable in blood and therefore were presumed somatic
were 89% null, 3% in-frame, and 8% methylation of
the promoter.
Of 126 sporadic retinoblastoma tumors in which mu-
tations were identified, the second allele was mutated by
loss of heterozygosity (LOH) in 66 (52%). Interestingly,
the likelihood that the M2 event would be LOH varied
with the type of M1 event. Only 23% of tumors with
M1 whole-gene deletions and only 27% of tumors with
exonic deletions showed LOH, whereas 88% of tumors
in which M1 was methylation of the promoter showed
LOH.
The distribution of the 229 germline mutations is il-
lustrated in figures 1 and 2 and table 1. The majority
(93% for bilaterally affected probands and 57% for uni-
laterally affected probands) were null mutations that
predict a truncated protein or mRNA with a premature
stop codon that is anticipated to be degraded by non-
sense-mediated decay (NMD) (Culbertson 1999; Frisch-
meyer and Dietz 1999; Hentze and Kulozik 1999). These
null mutations, including whole allele deletions, dele-
tions involving one or more exons and splice mutations
(fig. 1), small frameshifting intraexonic insertions and
deletions, and nonsense mutations (fig. 2), were distrib-
uted throughout the RB1 gene. Most of the missense
mutations were clustered in RB1 domains A and B,
which are known to be important in the regulation of
transcription by the RB1 protein product, pRB (Di-
Ciommo et al. 2000).
The 223 somatic null mutations (M2 for germline
cases or M1/M2 for nongermline cases) were similarly
distributed between mutation types, except that meth-
ylation of the promoter accounted for 8% of somatic
mutations (table 1). We have tested blood from 7 of 28
probands with germline mutations in whom we have
not found an RB1mutation, and none showed promoter
methylation (data not shown).
Excluding the 66 mutant alleles due to LOH, of 386
mutant RB1 alleles (235 germline and 151 somatic),
45% occurred only once (123 germline and 52 somatic
p 175 overall). One-third of the “recurrent” mutations
were large deletions or methylation of the promoter and
were not defined at a nucleotide level (table 2). All of
the 13 point mutations that occurred four or more times
involved CrT transitions at CpG dinucleotides attrib-
uted to deamination of 5-methylcytosine (Rideout et al.
1990; Schmutte and Jones 1998). Twelve of these mu-
tations affected arginine codons, and one created a splice
mutation (13541GrA).
Molecular analysis of tumor tissue in one unilaterally
affected patient identified three individual RB1 muta-
tions: heterozygous deletion of all exons and the pro-
moter, and S795X and 713delAA, both presumed to be
hemizygous (rather than homozygous). Since tumors are
clonal, it is possible that the three mutations represent
two different subclones with different M2 mutations but
with the same M1 deletion. None of the three mutations
were present in the patient’s blood. This is the only ret-
inoblastoma tumor in which more than two RB1 mu-
tations were observed, but we have not exhaustively
looked for more than two mutations. Mutation analysis
of tumor DNA is discontinued once two genetic changes
predicted to be causative have been identified.
Table 1
Characterization of 452 Mutant RB1 Alleles from 378 Probands with Retinoblastoma
MUTATION TYPE
BILATERAL AND FAMILIAL
UNILATERAL GERMLINE
(STUDIED BLOOD)
UNILATERAL GERMLINE
(STUDIED TUMOR)
MUTANT
ALLELES
IN TUMORS
(UNILATERAL)
UNILATERAL SPORADIC
(STUDIED TUMOR)
TOTAL
COUNTaBilateral
% M1 Found
for Probands
with Bilateral
Disease
Familial
Unilateral
Sporadic
Germline
Unilateral
% M1 Found
for Probands
with Unilateral
Disease
No. Somatic
M1/M2
Including
LOH %
No. of
Tumors with
LOH/Total
Tumors %b
Null:
Whole-gene deletions (Pr27) 11 6 0 4 13 33 29 13 6/26 23
Exonic deletions 14 7 0 0 0 18 18 8 3/11 27
Intraexon deletions or insertions 47 24 4 2 20 41 39 17 13/21 62
Splice mutation within two bases of exon 25 13 1 2 10 21 19 9 5/10 50
Splice mutation more than two bases from exon 5 3 0 0 0 1 1 0 0/0 NA
Nonsense mutations 84 42 2 2 13 95 93 42 29/45 64
Total 186 93 7 10 57 209 199 89 56/113 50 402
In-frame (not truncating):
Deletion 3 bp, exon 4, 13, 24–25 2 1 2 0 7 2 2 1 1/1 100
In-frame splice deletions 0 0 0 0 0 0 0 0 0/0 NA
Missense mutations 10 5 7 3 33 8 5 2 2/4 50
Total 12 6 9 3 40 10 7 3 3/5 60 31
Promoter:
Promoter sequence mutations 1 1 1 0 3 0 0 0 0/0 NA
Methylation 0 0 0 0 0 17 17 8 7/8 88
Total 1 1 1 0 3 17 17 8 7/8 88 19
Total alleles identified 199 17 13 236 223 452
Total Tumors with LOH 66/126 52
NOTE.—Apparent discrepencies in totals are due to rounding.
a The values summed to make up each total are shown in boldface italic type.
b NA p not applicable.
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Figure 1 The distribution, within the RB1 cDNA and promoter, of 111 different missense mutations and small insertions and deletions
in the germline of 165 persons. Ninety-five families had unique mutations. Fourteen recurrent mutations that affected 70 independent families
are shown in black; 14 in-frame mutations are outlined in black; R661W is both recurrent (all seven occurrences in germline) and in-frame,
indicated by a wide black border.
Genotype-Phenotype Correlations
For 93% (186/199) of probands with bilateral reti-
noblastoma, the germline RB1 mutant alleles were
“null” (table 1) and were expected to result in premature
truncation of translation and unstable mRNA (Dunn et
al. 1989b) due to nonsense-mediated decay (Culbertson
1999; Frischmeyer and Dietz 1999; Hentze and Kulozik
1999), resulting in no detectable protein. Of the 203
probands with null germline mutations, 92% had bi-
lateral tumors, whereas only 50% (12/24) of probands
with in-frame mutations developed bilateral tumors (ta-
ble 1). The diseased eye ratio (der; the ratio of the sum
of affected eyes to the number of mutation carriers in a
family) (Lohmann et al. 1994) is 1.9 for null RB1 alleles
and !1.5 for in-frame and promoter mutant alleles.
The recurrent missense mutation R661W occurred in
7 (3%) of 235 unrelated families with germline muta-
tions (table 2). Four of the seven R661W probands were
unilaterally affected (der 1.6). Of 30 unilateral germline
probands, four (13%) had R661W. This mutation has
been associated with reduced penetrance (Lohmann et
al. 1992; Onadim et al. 1992), and the protein product
of the R661W allele has been shown to have partial
activity (Otterson et al. 1997; Whitaker et al. 1998).
Therefore, the patients with sporadic unilateral retino-
blastoma and with R661W germline mutations can be
considered the founders of families with reduced pene-
trance. Of the 16 missense mutations, 13 involved the
A/B “pocket” domain of pRB (15 germline missensemu-
tations are shown in fig. 1), which is critical in the in-
teraction of pRB with the transcription factor E2F
(DiCiommo et al. 2000). For example, in vitro studies
of R661W showed decreased binding to the transcrip-
tion factor E2F1 but a retained ability to undergo cyclin-
mediated phosphorylation (Otterson et al. 1997).
Lysine substitution for valine (V654L) resulted in re-
duced penetrance, with a der of 0.5, but substitution of
glutamic acid for valine at the same position has been
shown to yield a more highly penetrant phenotype (Loh-
mann, personal communication). A V654Lmutant allele
was also heterozygous with the null allele R556X in a
unilateral nonhereditary tumor, consistent with the con-
cept that LOH for the reduced-penetrance V654L allele
might be insufficient for tumorigenesis (DiCiommo et al.
Richter et al.: Clinical RB1 Gene Mutation Detection 259
Figure 2 The distribution within the RB1 cDNA and promoter of 41 splicing mutations and large deletions identified in the germline of
65 probands with retinoblastoma. The mutations in black occurred in more than one independent family; the number of occurrences is in
brackets.
2000). Functional studies may provide greater insight
into the importance of this valine residue, which lies
90%–100% buried (Lee et al. 1998) within the pocket
domain.
Of 15 probands with complete deletion of RB1
(delPr27), only 11 (73%) had bilateral retinoblastoma.
The delPr27 mutation accounted for 13% (4/30) of
total unilateral germline mutations but only 6% of all
bilateral germline mutations (table 1). The tendency for
total deletions to cause fewer tumors has been hypoth-
esized to be due to contiguous deletion of an adjacent
unknown gene that is essential for cell survival (Di-
Ciommo et al. 2000). Although LOH is the M2 event
in 52% of all retinoblastoma tumors studied, it occurred
in only 22% of whole-gene deletions. Presumably, LOH
for a deletion that encompassed both RB1 and the ad-
jacent “lethal” gene would result in total loss of the
essential gene, causing cell death rather than retino-
blastoma. Therefore, fewer tumors would form, result-
ing in a higher frequency of unilateral disease. Tumors
would result only if M2 were a different mutationwithin
RB1, leaving the unidentified lethal gene intact.
Sensitivity to Identify RB1 Mutation(s) in Probands
In total, the combination of molecular techniques de-
scribed above characterized 452 mutant RB1 alleles (ta-
ble 3). We identified the germline mutation in 199 of
224 probands with bilateral retinoblastoma (89% sen-
sitivity) and in 17 of 20 (85%) probands with unilateral
familial retinoblastoma. In the tumors from 134 patients
with unilateral sporadic disease, we characterized 236
mutated alleles (89% sensitivity to discover mutant al-
leles). The germline status in 112 (84%) of these 134
patients was determined. No mutations were detected in
the tumors of eight probands with unilateral sporadic
disease. In tumors of 14 probands with unilateral spo-
radic disease, we characterized only one mutant allele
that was not detected in blood. These 22 cases are con-
sidered incomplete. Thirteen (12%) of the 112 probands
with unilateral, sporadic disease had germline mutations
despite the absence of family history.
QM-PCR Analysis
QM-PCR is sensitive to insertions and deletions rang-
ing in size from 2 bp (fig. 3) to the whole RB1 gene.
QM-PCR covering the whole gene in six multiplex sets
of 1–8 exons (2, 1, 8, 6, 6, and 5 exons in six multiplex
groups) detected 31% of the mutant alleles in our sam-
ple. However, QM-PCR is a more powerful assay of
allelic copy number for some exons than for others (table
4). For 19 exons, QM-PCR distinguished correctly be-
tween samples that have one allele and samples that have
two alleles, at a 97% confidence level. For 22 exons,
QM-PCR distinguished correctly at a 95% confidence
level. For four exons, QM-PCR showedmoderate power
(confidence level 60%–80%), and, for exon 1, QM-PCR
did not discriminate between one-copy samples and two-
copy samples. We have developed a replacement set of
four QM-PCR multiplex sets (Q1–Q4) with 1–13 exons
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Table 2
Recurrent Mutations Identified by QM-PCR and Bidirectional Sequencing
TYPE OF MUTATION AND TEST
EXON/
PROMOTER MUTATION TOTAL SOMATIC
GERMLINE
All Unilateral Bilateral
Small deletions:
QM-PCR 9 1066delG 2 0 2 1 1
QM-PCR 11 1259delCA 2 0 2 0 2
Nonsense mutations:
Sequence 10 R320X 18 6 12 0 12
Sequence 15 R467X 15 8 7 2 5
AS4-PCR 18 R579X 13 6 7 1 6
AS4-PCR 14 R455X 11 6 5 1 4
Sequence 14 R445X 10 3 7 0 7
AS4-PCR 11 R358X 8 3 5 0 5
Sequence 23 R787X 7 3 4 0 4
AS4-PCR 8 R251X 8 4 4 1 3
Sequence 17 R552X 6 4 2 0 2
Sequence 17 R556X 4 2 2 0 2
Sequence 23 Y790X 3 2 1 0 1
Sequence 18 Q575X 2 2 0 0 0
Sequence 8 R255X 4 1 3 0 3
Sequence 17 W529X 2 1 1 1 0
Sequence 25 Q846X 2 1 1 0 1
Sequence 13 S443X 2 1 1 0 1
Sequence 10 E323X 2 0 2 0 2
Sequence 19 Q637X 2 1 1 0 1
Splice mutations:
Sequence 12 13531GrA 7 2 5 1 4
Sequence 23 26271GrT 2 0 2 0 2
Sequence 6 7451GrT 2 0 2 1 1
Sequence 6 678-1GrA 2 1 1 0 1
Missense mutations:
Sequence 20 R661W 7 0 7 4 3
Sequence 19 V654L 2 1 1 1 0
Promoter mutations:
Methylation Promoter Pmeth 10 10 0 0 0
Large deletions:
QM-PCR delPr27 38 22 16 5 11
QM-PCR del3r27 5 5 0 0 0
QM-PCR del18r27 3 2 1 0 1
QM-PCR delPr2 3 1 2 0 2
QM-PCR 17 del17 3 0 3 0 3
QM-PCR delPr17 2 1 1 0 1
QM-PCR 13 del13 2 0 2 0 2
No. of mutations that occurred more than once 211 99 112 19 93
% of mutant alleles 66 48 53 47
No. of mutations that occurred only once 52 123 17 106
% of mutant alleles 34 52 47 53
Total no. of mutant alleles excluding LOH 151 235 36 199
Tumors with LOH 61 5
Total no. of mutant alleles including LOH 212 41
each, to increase efficiency in mutation identification,
which are now being validated.
Allele-Specific PCR
Analysis of mutation type and distribution along the
RB1 gene revealed that, although the gene lacks hot
spots that would predict important functional domains,
13 point mutations recurred with significant frequency,
particularly CpG transitions (Cowell et al. 1994) (table
2). We developed AS4-PCR for four of these recurrent
mutations in one multiplex, which clearly distinguished
the specific alleles from the background level of wild-
type allele amplification (fig. 4). This multiplex is fast
and inexpensive, since only one PCR and one agarose
gel are required to detect 10% (40/401) of all mutant
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Table 3
Sensitivity of Combined Molecular Techniques to Identify RB1 Mutations
Bilateral
(Study Blood)
Familial
Unilateral
(Study Blood)
Sporadic
Unilateral
(Study Tumor) Total
No. of probands analyzed 224 20 134 378
No. of probands diagnosed 199 17 112 328
Sensitivity to diagnose proband 89% 85% 84% 87%
No. of alleles examined 224 20 266a 510
No. of mutant alleles identified (including LOH for tumors) 199 17 236 452
Sensitivity to identify allele 89% 85% 89% 89%
a Tumors from 134 patients with sporadic unilateral retinoblastoma contained 268 mutant alleles; however, for two
tumors, the first allele discovered was shown to be in the germline, so mutations were not identified in the second alleles.
alleles (12% of somatic and 8% of germline mutant
alleles).
Assay Order Analysis and Optimization
Our search for optimal orderings revealed statistical
dependence between assays in at least two ways. First,
characterization of some multiexon deletions requires
more than one multiplex, so the sensitivity of the next
multiplex depends on the subset of multiplexes already
performed. For example, multiplex Q2 scores 10, 13,
or 17 mutations, depending on which multiplexes pre-
cede it in the test order. Consequently, QM-PCR mul-
tiplexes cannot be optimally ordered by simply com-
paring test sensitivity.
We solved this problem by isolating the set of QM-
PCR multiplex permutations that achieves minimum
time to discovery. We ignored materials costs and time
differences, because each multiplex takes almost the
same time and incurs almost the same materials cost.
We found the unique best multiplex order to achieve
complete diagnosis for bilaterally affected families and
a different optimal order for unilaterally affected pro-
bands. After the QM-PCR multiplexes were ordered,
ranking proceeded for the entire list of tests by iteration,
comparing all test permutations with the order of QM-
PCR multiplexes constrained to the optimal order. We
found different optimal multiplex orders for the 199
proband germline RB1 mutations and the 112 patients
whose testing was completed by identification of somatic
mutations.
Second, statistical dependence appears when analyz-
ing sporadic unilateral mutations. In the 48% of tumors
that do not show LOH, we must search for two different
mutations. Any pair of mutations that occurs together
with more than random probability introduces history-
dependent sensitivity ranking, so the likelihood that the
next assay will complete the molecular characterization
of disease depends on which tests have already been
performed. We solved this problem by using an iterative
sort procedure that isolates minimum-cost orderings
(multiple answers are possible) through pairwise com-
parisons, widely known as a “bubble” sort. Though sev-
eral methods for sorting a static list of values are known
to be quicker than a series of iterative pairwise com-
parisons, in this case the ranking measure is not static
and changes with the sort order. Therefore, iterative pair-
wise comparisons are essential to ensure correct rank.
Our search for optimal orderings showed progressive
improvement. Initially, we naı¨vely performed the six
original QM-PCR multiplexes (M1–M6), then se-
quenced exons and the promoter in duplexes ordered by
casual observation of the exons most likely to contain
mutations. Because both RB1 mutant alleles must be
identified for tumors, we analyzed germline and somatic
mutations separately. Using the original naı¨ve method,
projected turnaround time was 6.4 wk for probands
with heritable (bilateral or familial unilateral) disease. If
sequence duplexes are interleaved between QM-PCR
multiplexes, projected turnaround time drops to 5.13
wk. Finally, with redesigned QM-PCR multiplexes (Q1–
Q4) and AS4-PCR, projected turnaround time is 2.7 wk.
Impact of RB1 Mutation Identification on Quality
of Health
Molecular analysis was useful to families with reti-
noblastoma in several ways. Thirteen of 29 offspring of
adult retinoblastoma survivors, who were tested at var-
ious stages of pregnancy or postnatally, were shown to
carry their family’s mutation. The offspring who did not
carry the RB1mutation did not develop retinoblastoma.
Four infants had the molecular test and were clinically
examined shortly after birth. All had tumors at birth
and, in the next few months, all developed bilateral tu-
mors that were treated with focal therapy and chemo-
therapy. One of the eight eyes was eventually enucleated.
Prenatal testing identified nine fetuses that carried the
family’s RB1 mutation. Five of these families, all of
whom had experienced children dying of retinoblastoma
or second primary tumors, chose termination of the
pregnancy. One family that had undergone a very neg-
262 Am. J. Hum. Genet. 72:253–269, 2003
Figure 3 Mutation detection using QM-PCR. A, Detection of a multiexonic deletion spanning at least exons 4–11, while exons 19 and
25 remain two-copy. B, Detection of a 2-bp deletion in exon 22 by QM-PCR.
ative experience with retinoblastoma terminated a preg-
nancy that carried the RB1 mutation and subsequently
delivered a baby without the mutation, who did not
develop tumors.
Four infants known to have RB1 mutant alleles were
delivered prematurely at ∼35 wk gestation, in order to
treat potential macular tumors early. One of the four
infants had a unilateral macular tumor at 36 wk ges-
tation. The other three children developed bilateral tu-
mors 1 mo to 1 year later. All eight eyes were treated
with laser and cryotherapy only, and all have 6/6 vision.
Only 13 of 112 (12%) unilaterally affected probands
with no family history of retinoblastoma were germline
carriers of one of the two RB1 mutations detected in
their tumor. None of the 99 unilateral probands whose
identified tumor mutations were not present in blood
developed retinoblastoma in the unaffected eye. Of all
germline RB1 mutation carriers, ∼10% (Sippel et al.
1998; Smith et al. 2000) are mosaic and might not be
detected by our screens. A 1.2% (10% mosaicism #
12% germline mutation in sporadic unilateral disease)
risk remains that a unilaterally affected patient in whom
the tumor mutations are not detectable in blood has
germline mosaicism, with 0.6% residual risk for the next
generation. Precise knowledge of RB1 mutations in the
tumor of a potentially mosaic unilaterally affected pro-
band would permit accurate testing of future offspring
for the same mutations.
Within our cohort of 212 nonfamilial probands with
germline mutations, 195% of parents tested normal for
their child’s mutation. One percent (10% mosaicism#
10% germline) of such parents could be mosaic, thereby
putting siblings at a 0.5% calculated risk (50% chance
of inheriting the mutant allele # 1.0% chance that the
parent who tests normal is mosaic) of inheriting the same
mutant RB1 allele as the proband. Since mosaicism can-
not be inherited, siblings and other relatives are at the
population risk to develop retinoblastoma if a unilat-
erally affected proband’s tumor mutation does not show
in blood.
Impact of RB1 Mutation Identification on Cost
of Health Care
To measure the impact of RB1 molecular testing on
health outcomes and health care costs for whole families,
we counted the number of surveillance examinations
performed on first- and second-degree child relatives for
a representative sample of 20 Ontario families (fig. 5).
For each family, we counted the number of examinations
saved by the molecular strategy and the net savings in
direct surveillance cost.
With molecular testing, individual relatives required
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Table 4
Statistical Power of Test for Allelic Quantity by QM-PCR
EXON
TWO-
COPY
SAMPLE
SIZE
(n)
SMALLEST
a FOR
ZERO ba
(%)
CRITICAL
VALUE
(MEASURED
AS COPY
NUMBER)
IMPLIED %
CONFIDENCE
LEVEL
IMPLIED STATISTICAL POWERb
Strong
( )p 1 .95
Moderate
( ).60 ! p ! .95
Weak
( )0 ! p ! .60
7 78 0 1.2 100 X
19 78 0 1.2 100 X
27 72 0 1.2 100 X
3 72 0 1.3 100 X
12 80 0 1.4 100 X
15/16 80 0 1.4 100 X
25 78 0 1.4 100 X
9 72 0 1.5 100 X
5 78 2 1.2 98 X
8 78 2 1.2 98 X
10 78 2 1.2 98 X
24 72 2 1.2 98 X
26 72 2 1.2 98 X
23 67 2 1.3 98 X
17 80 2 1.5 98 X
4 78 3 1.1 97 X
22 72 3 1.3 97 X
6 72 3 1.4 97 X
20 70 3 1.5 97 X
11 78 4 1.3 96 X
13 70 5 1.2 95 X
14 72 5 1.3 95 X
2 48 23 1.7 77 X
21 79 23 1.7 77 X
18 80 34 1.8 66 X
P 63 38 1.9 62 X
1 65 94 2.3 6 X
Count total 22 4 1
a a p the probability of falsely categorizing two-copy DNA as one-copy DNA; b p the probability of falsely
categorizing one-copy DNA as two-copy DNA.
b p p frequency not two-copy.
fewer or no examinations for clinical surveillance. In
the 20 families, 88 children avoided a total of 313 EUA,
and 107 children avoided 852 clinic examinations (fig.
5A). The mean savings in health care spending for all
20 families was Can$6,591 (US$4,200) per family (fig.
5B). In 12 of 20 families surveyed, molecular analysis
saved Can$1,000–$38,000. In the remaining eight
families, surveillance with molecular analysis cost
Can$1,000–$6,300 more than conventional surveil-
lance. Even when the molecular strategy cost more, the
quality of care was better for families in which molec-
ular diagnosis allowed children to avoid clinical ex-
aminations. In five families, children at risk were rel-
atively few or relatively old, so the usual savings were
diminished. In one family that carries a low-penetrance
mutation, a large proportion of people in the pedigree
needed to be tested. In two families whose mutant RB1
allele was not identified by all the assays performed,
the molecular route cost more because no clinical ad-
vantage was obtained despite the work.
Discussion
Using a combination of molecular techniques, we de-
tected 452 RB1 mutations in clinical samples from 378
probands with retinoblastoma (tables 1 and 3). Twenty-
seven of these mutations that we previously published
are included in a review of 368 reported RB1mutations
posted in the RB1 Gene Mutation Database (Lohmann
1999). A meta-analysis of germline mutations of 192
patients (Harbour 1998) reported that 90% of muta-
tions were likely to result in the absence of RB protein.
We confirm that mutations likely to result in residual
protein (missense mutations, in-frame deletions and
splice abnormalities, and promoter mutations) are rare
(7%) in bilaterally affected probands but represent 43%
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Figure 4 Multiplex AS4-PCR for rapid detection of recurrent mutations in RB1. Four samples from patients with retinoblastoma (patients
A–D) and two control normal samples were tested by AS4-PCR containing primers specific for the recurrent mutations R455X (730 bp), R579X
(287 bp), R358X (251 bp), and R251X (202 bp). Strong amplification occurred when the mutation identified by the specific PCR primer was
present. Unaffected individual 1 and patient D also show low levels of cross-hybridization to the wild-type alleles with the primers for R455X
and R358X.
of germline mutations in unilaterally affected probands.
Neither of the previous studies reports whole-exon or
multiexon deletions, which accounted for 14% of the
bilaterally affected probands in our study. It is likely that
the techniques used in the previous studies were insen-
sitive to exon copy number. Karyotype analysis will de-
tect 5%–7% of RB1 mutations that are large rearrange-
ments but has insufficient resolution for small exonic
deletions.
Of 15 missense mutations, 13 are clustered in the A/
B pocket and the intervening spacer region, confirming
that in-frame mutations favor critical regions of RB1.
At least three of the missense mutations (R661W,
V654L, and C712R) have been associated with reduced
penetrance (DiCiommo et al. 2000). Only one of the
missense mutations was recurrent, R661W. In addition,
the mutations identified in the germline of unilaterally
affected children, 43% of which are in-frame, can also
be considered to have reduced penetrance. The recurrent
mutations, including R661W, all involve CrT transi-
tions (fig. 1), usually resulting in CGA (arginine) mu-
tating to TGA (stop codon) (Cowell et al. 1994). Of 46
arginine codons in RB1, 14 are encoded by CGA/G,
and 13 of 14 are targets for recurrent mutations. The
14th CGA arginine is in exon 27. Since no mutations
are observed yet in exons 26 and 27, change in the C-
terminus of the RB protein may be insufficient to induce
retinoblastoma.
We show that QM-PCR is a very efficient method to
identify copy number and exon size changes and is ame-
nable to tight statistical control for accuracy and sen-
sitivity in clinical application. Mutation identification
strategies for other genes, such as BRCA1 and MLH1
(Nakagawa et al. 2002), have not efficiently identified
this class of mutation. Generation of stable murine-hu-
man hybrid cell lines carrying selected human chro-
mosomes in only a single copy (Yan et al. 2000) or by
limiting dilution of DNA to a single template (Zhou et
al. 2002) has been used to obtain copy-number muta-
tions in the hMSH1 and hMSH2 genes in patients (Yan
et al. 2000; Nakagawa et al. 2002). However, these
techniques are extremely labor- and technology-inten-
sive and are unlikely to achieve cost effectiveness in
health care applications. QM-PCR would have identi-
fied these mutations efficiently without the complexity
of producing hybrids. We have used QM-PCR, in ad-
dition, to efficiently identify narrow regions of common
genomic gain (Chen et al. 2002) and loss (D. Chen, M.
Harmandayan, C. Lee, M. Marchong, and B. Gallie,
unpublished data), other than the RB1 changes, that
occur commonly in retinoblastoma. Thus, QM-PCR
presents clear opportunity for multiple uses in mutation
identification and in studies of cancer prognosis.
Of 126 sporadic retinoblastoma tumors in which mu-
tations were identified, the second allele was mutated
by LOH in 66 (52%). Interestingly, the likelihood that
the M2 event would be LOH varied with the type of
M1 event. Only 23% of tumors with M1 whole-gene
deletions and only 27% of tumors with exonic deletions
showed LOH, whereas 88% of tumors in which M1
was methylation of the promoter showed LOH.
Exons have been screened for mutations through use
of a variety of techniques, including SSCP analysis
(Hogg et al. 1992; Shimizu et al. 1994; Blanquet et al.
1995; Asher et al. 1996), pulsed field gel electrophoresis
(Janson and Nordenskjold 1994), denaturing gradient
gel electrophoresis (Blanquet et al. 1995), heteroduplex
analysis (Szijan et al. 1995; Zhang and Minoda 1995),
and Southern blotting (Blanquet et al. 1991; Kloss et
al. 1991; Zajaczek et al. 1999). Aside from direct se-
quencing of exons (Yandell et al. 1989; Zajaczek et al.
1999), the majority of these methods rely on an initial
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Figure 5 Impact of molecular RB1 testing. A, Histograms of the number of examinations avoided because of molecular results. Clinic
examinations are shown in white bars, EUAs in black bars. B, Histogram of direct surveillance costs saved for 20 families because of molecular
RB1 testing. Mean savings was Can$6,591 per family (horizontal line). Families with bilateral and familial retinoblastoma are shown in white
bars, and families with unilateral nonfamilial disease are shown in bars with oblique hatches. The molecular strategy cost more than conventional
surveillance for two families in which all assays failed to show the proband’s mutation (dotted bars) and for six families in which at-risk family
members were few in number or significantly older than the proband.
exon screen followed by sequencing of suspect amplified
fragments. Denaturing high performance liquid chro-
matography, which appears to be efficient at finding
heterozygous mutations once optimized for the gene be-
ing studied (Bennett et al. 2001; Han et al. 2001), has
been effectively applied to RB1 mutation screening (D.
Lohmann, personal communication).
We have used double-exon sequencing without a pre-
screen for exonic changes and found that this approach
could be efficient if test order is optimized. By analysis
of the RB1 mutational spectrum and calculation of the
frequency of occurrence for mutation types that would
be refractory to characterization by exon sequencing,
we were able to use a statistical approach for identifying
a combination of assays to find mutations with the
smallest number of required assays. This requires that
QM-PCR be performed at predictable stages between
the sequencing of particular exons. Statistical analysis
also showed that time to the discovery of a mutation
was hindered when this approach was not used.
Detection of RB1 mutant alleles has required the
analysis of genomic DNA, because, in blood, mRNA
from null alleles was undetectable (Gallie et al. 1988;
Dunn et al. 1989a; Kato et al. 1994). This has been
attributed to message instability due to NMD (Cul-
bertson 1999; Frischmeyer and Dietz 1999; Hentze and
Kulozik 1999). However, null alleles are easily detected
in mRNA in retinoblastoma tumors. This may occur
either because NMD is less active in tumors or because
the mRNA from tumor cell lines was prepared without
the delay usual for blood samples, allowing no time for
NMD, or because the absence of pRB leads to upregula-
tion of transcription to levels where even degrading
mRNA is detectable by PCR (Dunn et al. 1989b). Sta-
bilization of mRNA showing premature truncation of
translation by puromycin or cycloheximide (Carter et
al. 1995) prior to RT-PCR might allow detection of
mRNA from null alleles in blood, adding efficiency and
a potential increase in sensitivity of RB1 mutation
identification.
The optimization of multiple steps for mutation de-
tection in large genes may be generalized to other genes
that cause disease with a high frequency of private null
alleles, such as BRCA1 and BRCA2. Mutation identi-
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fication for BRCA genes is similar to RB1, in that
knowledge of carrier status can provide very real ad-
vantages to the family (Kutner 1999) and there are
many ways that the genes can be mutated, including
copy number changes. However, the advantages we
have in testing of families with retinoblastoma (i.e., only
one gene [RB1], 195% penetrance to get tumors for
null alleles, all tumors showing loss of both alleles, clear
benefit in health outcome, effective treatment in the first
years of life) are not so obvious for familial breast can-
cer (multiple genes, including BRCA1, BRCA2, and
CHEK2 [Liede et al. 2002; Meijers-Heijboer et al.
2002]; penetrance variable and much less than 90%;
somatic tumor mutation heterogeneity; health benefit
and treatment less obvious; and inhibition of optimi-
zation of molecular testing due to patenting of the
BRCA1 and BRCA2 genes). The exonic copy number
changes that we detect readily with QM-PCR in RB1
are common in the BRCA genes (Gad et al. 2001) but
are not commonly looked for in screening strategies
(Hegde et al. 2000).
Genotype-phenotype correlations can be used to fur-
ther optimize time to diagnosis of the mutation. For
example, for families with a reduced number of affected
eyes and a high number of unilaterally affected children,
the order of assays can be further optimized to reflect
certain genotype-phenotype correlations. Thirteen per-
cent of families with reduced penetrance carry the
R661W mutation, in comparison with 1% of bilateral
families with full penetrance and expressivity. In addi-
tion, two families in our study showed the 7451GrT
mutation (IVS61GrT) leading to a stop codon in
exon 7 and the reported characteristic highly unusual
inheritance pattern (Klutz et al. 2002). Whenever this
splice mutation is paternally inherited, it shows high
expressivity and nonsense-mediated decay of one copy
of the mRNA, as observed for other null RB1 alleles.
Conversely, maternal inheritance of the mutation is as-
sociated with extremely low expressivity, and the mis-
spliced message (missing exon 6) is easily detectable.
We already base the assays on phenotype, in that bi-
lateral familial and unilateral nonfamilial patients are
approached very differently. However, we can further
optimize on the basis of genotype-phenotype knowl-
edge. For example, we can now test unilaterally affected
familial probands first for total deletion and R661W,
since these two assays would find 26% of germline al-
leles. Similar test order would also be applicable to the
study of unilateral, nonfamilial tumors, to optimize time
to discover the rare germline mutations in the first mem-
ber of a family with reduced penetrance.
Intronic translocations, which remain undetectable
by our current techniques, may account for some of the
10% of families for which no mutation was identified.
FISH, a method well suited to the detection of trans-
locations, has not yet revealed any translocations in
samples in which all our assays were negative. Some of
the unidentified 11% of germline alleles are likely to be
accounted for by mosaicism. Given the suggestion that
mosaicism for RB1 mutations occurs in ∼10% of fam-
ilies (Sippel et al. 1998), we may be close to the max-
imally achievable sensitivity for detection of germline
mutations, but mosaicism can not account for the miss-
ing tumor mutations or familial mutations. Our se-
quencing is sensitive to 20%–30% heterogeneity, and
therefore we can sometimes identify mosaicism (Sippel
et al. 1998), so when no obvious mutation was found,
we reviewed the primary data for possible mosaicism.
The 18% of unidentified somatic mutant alleles in tu-
mors may be accounted for by regulatory mutations in
regions not yet known to be important in RB1 function.
Human papilloma virus (HPV) E7 protein binds and
inactivates pRB in the process of deregulation of the
cell cycle (Dyson et al. 1989). In a recent study, an
apparent correlation of PCR-detectable HPV sequence,
as well as both the lower proliferation indices and the
lower risk of extraocular disease in 14 of 39 retino-
blastoma tumors, led to the hypothesis that the virus
may play a role in sporadic disease (Orjuela et al. 2000).
We are currently investigating the DNA of unilaterally
affected patients for whom no oncogenic mutations
were found, to look for evidence of HPV.
High assay sensitivity to discover mutant allele(s) is
crucial to clinical implementation of RB1mutation iden-
tification. The costs of failing to identify a mutation in-
clude substantial wasted lab costs, the costs of counseling
the family, and a significant opportunity cost, since ir-
replaceable tumor samples must be used for patients with
unilateral, sporadic disease. We report 89% sensitivity to
identify RB1 mutant alleles, the highest yet reported.
Other investigators indicate sensitivity to identify mutant
RB1 alleles between 40% (Sippel et al. 1998) and 80%
(Mateu et al. 1997; Harbour 1998; Lohmann 1999; Za-
jaczek et al. 1999; Alonso et al. 2000; Najera et al. 2001).
Linkage studies indicate that the unidentified mutant al-
leles in probands with hereditary retinoblastoma still in-
volve the RB1 gene, even when mutations are not found.
When all assays were negative, failure to identify a mu-
tant allele was reported to the referring professionals, and
work continued to identify the RB1 mutation on a re-
search basis.
The optimization algorithms provide a practical tool
to evaluate prospective new tests. For example, the im-
pact of developing multiplex AS4-PCR on test sensitiv-
ity, costs and turnaround time was assessed prospec-
tively prior to use of the assay on clinical samples. The
analysis showed that AS-PCR would be more effective
than direct sequencing only if multiple point mutations
with a relatively high frequency of occurrence were as-
sayed in a single reaction. Thus, we implemented AS4-
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PCR only after finding a combination of experimental
conditions that allowed four recurrent nonsense mu-
tations to be multiplexed and detected in a single aga-
rose gel (fig. 4). If the 13 mutations that have occurred
four or more times were tested together in one or two
multiplex reactions, 112 of 402 (28%) RB1 mutations
could be detected. At present, we still confirm the AS4-
PCR results by sequencing the suspect mutant allele,
but no false positives have yet been found.
Our analysis demonstrates a significant positive im-
pact on health care costs ofRB1mutation identification.
In 1994, we calculated that the cost of molecular testing
for a family was equal to the cost of conventional sur-
veillance for all children of the same generation as the
proband. With the benefit of the proband’s analysis, the
cost of molecular surveillance for future generationswas
significantly lower than the cost of conventional screen-
ing (Noorani et al. 1996). We now show that, on av-
erage, molecular testing resulted in direct health savings
equivalent to Can$6,591 (US$4,200) per family, before
counting the benefit to children not yet born. These
savings estimates clearly underestimate the true savings
achieved by molecular testing if morbidity and indirect
costs to families were measured. For 12/20 families,
there was a net monetary benefit due to excluding chil-
dren from EUAs and clinical exams, and for eight fam-
ilies there was a net increase in costs. However, 18 of
the 20 families benefited from molecular testing by
avoiding clinic examinations with inherent risk and by
saving time away from work and travel, two of the
many indirect costs not measured. We were unable to
detect the proband’s mutation for 2 of 20 families, con-
sistent with our observed sensitivity. These two families
incurred testing costs but attained no benefit.
Since the initial analysis of these data in 1994, the
cost of conventional care has continued to rise, while
the cost of molecular testing has decreased. We antici-
pate that the disparity in cost between conventional and
molecular screening will continue to grow as new ge-
netic methods further optimize testing. Our work shows
the feasibility of using cost-effective improvements in
the quality of care to justify changes to the standard of
care and shows that new technology is not always more
expensive.
Optimization of RB1 mutation detection decreases
test costs, decreases turnaround time, and increases the
likelihood of clinical implementation. We have found
that the spectrum of mutations, cost of methodology,
sensitivity, efficiency, and phenotype-genotype correla-
tions must all be considered before a truly comprehen-
sive approach to mutation detection can be applied ef-
fectively and reliably in a clinical context. These factors
override single, superficial factors like technical sophis-
tication or cost efficiency.
Responsible public health care policy requires criteria
such as the following, to ensure effective use of molec-
ular testing (Secretary’s Advisory Committee onGenetic
Testing 2000; Foreman et al. 2001): (i) effectiveness to
predict illness in a specific patient group, (ii) demon-
strated technical competency, (iii) improved health out-
comes as a result of testing, (iv) beneficial psychological
impact, (v) appropriate pre- and post-test counseling,
(vi) ongoing development to continually improve tech-
nology, (vii) interlaboratory validation of sensitivity and
proficiency, and (viii) beneficial impact on health spend-
ing. The data presented in the present article support
implementation of RB1 mutation testing in routine
health care that meets such criteria.
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